The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor mutational burden assessed by a targeted NGS assay to predict benefit from immune checkpoint inhibitors in non-small cell lung cancer.
 
Sacha Rothschild
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Roche Pharma AG
 
Philip Jermann
Employment - Thermo Fisher Scientific
 
Spasenija Savic
No Relationships to Disclose
 
Kirsten Mertz
No Relationships to Disclose
 
Alfred Zippelius
No Relationships to Disclose
 
Luca Quagliata
No Relationships to Disclose
 
Lukas Bubendorf
Stock and Other Ownership Interests - Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD (Inst); Roche (Inst)
Research Funding - MSD (Inst); Roche (Inst)